NCT02295397

Brief Summary

Patients with history of a food allergy to hazelnut, walnut or celeriac will undergo food provocation with a dose of the allergenic food to which 5% of the respective food allergic population (ED05) has been calculated to respond with allergic reactions (single shot study). In patients with a hazelnut or peanut allergy a double-blind placebo controlled food challenge with cookies containing either placebo or hazelnut and peanut respectively will be performed to determine threshold levels eliciting an allergic reaction. The results for threshold levels determined by cookie matrix will be compared to the results gained from the EuroPrevall project (matrix comparison study). In patients with a walnut allergy double-blind placebo controlled provocation with walnut will be combined with the intake of proton pump inhibitor (PPI) or with placebo to assess the impact of PPI on the threshold level and on the clinical manifestation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
72

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2014

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2014

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

November 11, 2014

Completed
9 days until next milestone

First Posted

Study publicly available on registry

November 20, 2014

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2017

Completed
Last Updated

May 11, 2017

Status Verified

May 1, 2017

Enrollment Period

2.3 years

First QC Date

November 11, 2014

Last Update Submit

May 10, 2017

Conditions

Keywords

Food provocationMatrix effectED05AllergyProton Pump Inhibitor

Outcome Measures

Primary Outcomes (1)

  • numbers of patients reacting to ED05 in hazelnut, walnut, celeriac allergy

    November 2014 to February 2017, up to 27 months

Secondary Outcomes (2)

  • numbers of patients reacting to a defined dose of peanut and hazelnut in titrated challenges

    November 2014 to February 2017, up to 27 months

  • Change in the threshold dose of walnut that induces an allergic reaction after the intake of therapeutic doses of omeprazole Change in the severity of walnut allergy after the intake of therapeutic doses of omeprazole

    February 2015 to February 2017, up to 27 months

Study Arms (1)

food provocation

EXPERIMENTAL

open and placebo-controlled food challenges

Other: food

Interventions

foodOTHER

food provocation, skin testing, blood sampling

food provocation

Eligibility Criteria

Age5 Years+
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Signed informed consent
  • For single shot study: history of a hazelnut, walnut, celeriac allergy due to an unequivocal accidental exposure with typical acute allergic reaction within the preceding 2 years and positive allergen-specific skin prick test/specific Immunoglobulin E or recent positive oral food challenge with hazel, walnut or celeriac within previous 2 years in children \<16 years, but no time limit specified for adults
  • For matrix comparison study: history of peanut or hazelnut allergy
  • For walnut/PPI study: history of walnut allergy. The minimum age for this study is 18 years

You may not qualify if:

  • Severe disease (heart, liver, kidney), acute febrile infection
  • Intake of Ketotifen (past 2 weeks), corticosteroids (past 2 weeks), histamine-1-receptor blocker (past 3 days apart first generation past 7 days)
  • Anaphylactic reaction (past 4 weeks)
  • Uncontrolled bronchial asthma, forced expiratory volume \< 70% predicted
  • Pregnancy
  • Acute infection or allergy
  • Uncontrolled atopic dermatitis
  • Chronic urticaria
  • Mastocytosis
  • Uncontrolled hypertension

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Allergy Unit, Department of Dermatology, University Hospital

Zurich, 8091, Switzerland

Location

MeSH Terms

Conditions

Food HypersensitivityHypersensitivity

Interventions

Food

Condition Hierarchy (Ancestors)

Hypersensitivity, ImmediateImmune System Diseases

Intervention Hierarchy (Ancestors)

Diet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Officials

  • Clare Mills, Coordinator

    University Manchester

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 11, 2014

First Posted

November 20, 2014

Study Start

November 1, 2014

Primary Completion

February 1, 2017

Study Completion

February 1, 2017

Last Updated

May 11, 2017

Record last verified: 2017-05

Locations